Table 1 Demographic and clinical characteristics of patients in the Cancer Genome Atlas papillary thyroid cancer cohort and validated papillary thyroid cancer cohort
From: Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma
Clinicopathological features | TCGA(N = 507) | Validated Cohort(N = 75) |
|---|---|---|
Age (year) | ||
Mean (SD) | 47.26 (15.78) | 44.09 (12.65) |
< 55岁 | 340 (67.06%) | 57 (76.00%) |
≥ 55岁 | 167 (32.94%) | 18 (24.00%) |
Gender, n (%) | ||
Male | 136 (26.82%) | 19 (25.33%) |
Female | 371 (73.18%) | 56 (74.67%) |
Stage, n (%) | ||
Stage I | 285 (56.21%) | 61 (81.33%) |
Stage II | 52 (10.26%) | 8 (10.67%) |
Stage III | 114 (22.49%) | 4 (5.33%) |
Stage IV | 55 (10.85%) | 2 (2.67%) |
Unknown | 2 (0.39%) | 0 (0.00%) |
T status, n (%) | ||
T1 | 144 (28.40%) | 46 (61.33%) |
T2 | 167 (32.94%) | 5 (6.67%) |
T3 | 171 (33.73%) | 14 (18.67%) |
T4 | 23 (4.54%) | 10 (13.33%) |
TX | 2 (0.39%) | 0 (0.00%) |
N status, n (%) | ||
N0 | 231 (45.56%) | 25 (33.33%) |
N1 | 226 (44.58%) | 50 (66.67%) |
NX | 50 (9.86%) | 0 (0.00%) |
M status, n (%) | ||
MO | 283 (55.82%) | 73 (97.33%) |
M1 | 9 (1.78%) | 2 (2.67%) |
MX | 215 (42.41%) | 0 (0.00%) |